Assertio Holdings Inc

Assertio Holdings faces a double‑edged future: potential Russell Microcap upgrade could lift shares, while a new shareholder‑rights investigation may reshape its governance and capital structure.

Assertio Holdings’ acquisition by Garda sparks mixed analyst sentiment—can a $125M deal turn its negative earnings into profit? Discover the risks and upside.

Assertio Holdings regains Nasdaq compliance, boosting investor confidence amid volatile pharma market—see how its stock, financials, and U.S. focus shape future prospects.

Assertio Holdings Inc. announces a 1‑for‑15 reverse stock split on Dec. 26, 2025 to maintain its Nasdaq listing, boost share price, and fuel growth with Rolvedon.

Assertio Holdings Inc has outlined its 2025 transformation priorities, aiming to reduce legal exposure and maintain revenue guidance, amidst a challenging financial landscape and fluctuating stock price.